ALK and non-small cell lung carcinoma: In the phase 1/2 study, 15 of the 79 patients with ALK+ NSCLC died within 30 days of the last dose of brigatinib; two deaths were found to be possibly related to brigatinib (unexpected death on day 568 in a patient receiving 90 mg once daily and sepsis on day 541 in a patient allocated to 180 mg once daily with 7-day lead-in at 90 mg).